- Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
- Compugen to Participate in Two Upcoming Investor Conferences
- Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
- Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024
- Compugen Reports Fourth Quarter and Full Year 2023 Results
- Compugen to Present at the Leerink Partners Global Biopharma Conference 2024
- Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024
- Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer
More ▼
Key statistics
On Sunday, Compugen Ltd (CGEN:TLV) closed at 713.00, -39.32% below its 52-week high of 1,175.00, set on Mar 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 716.60 |
---|---|
High | 729.70 |
Low | 710.30 |
Bid | 711.00 |
Offer | 713.00 |
Previous close | 736.20 |
Average volume | 82.97k |
---|---|
Shares outstanding | 89.53m |
Free float | 84.72m |
P/E (TTM) | -- |
Market cap | 637.66m ILS |
EPS (TTM) | -0.8136 ILS |
Data delayed at least 20 minutes, as of Apr 21 2024 13:49 BST.
More ▼